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In a recent issue of Nature, Tachibana et al. (2009) conducted chromosomal transfer into recipient primate
oocytes to yield live offspring or monkey ESCs with no contribution of donor mitochondria. The success
of this technique may increase demand for human oocyte donation for research.‘‘It will not work.’’ This statement repre-
sents the four words that best motivate
a scientist. Certainly, it is what I would
have said to Mitalipov’s team if they had
pitched me the idea of transferring the
spindle of one egg into the cytosol of
another, enucleated egg with the expec-
tation to produce a baby from THAT.
Even so, I would have been wrong.
Indeed, in their recent Nature article,
Tachibana etal. (2009) were able to remove
the chromosomes of a primate egg and
deliver a replacement set of chromosomes
from another donor female, a technique
they called spindle transfer (ST). Not only
were the authors able to fertilize the ST
eggs, they generated blastocysts healthy
enough to permit the derivation of embry-
onic stem cells (ESCs), and when the
embryos were transferred into the uterus
of a surrogate mother, healthy babies
were born. This is not an easy task; there
are multiple hurdles that had to be cleared
in order to achieve their success.
Ifwebow to the astronauts that repair the
Hubble telescope—and they deserve this
respect when they risk their lives by manip-
ulating equipment at a speed of 18,000
miles an hour and with no gravity—we
must also bow to the Oregon team that
accomplished ST. The authors managed
to take a primate egg, probably the most
valuable single cell in the body, maintain
its viability for hours, subject it to excep-
tionally precise microsurgery to remove
only 11 picolitres of cytosol, introduce the
precious cargo from a different oocyte by
performing a rendezvous maneuver with
the postsurgery egg still in the microscope,
fuse them, and subsequently trigger devel-
opment by injecting a sperm directly into its
cytosol. Four healthy monkeys were born
after that sequence; what a feat!
What can go wrong during this process?
In a nutshell, anything and everythingcould go wrong. If you are not aware and
respectful of the physiology of the egg,
the experiment is doomed. For starters,
the window of time to remove the chromo-
somes successfully is small. The egg must
maintain high levels of maturation pro-
moting factor (MPF) in order to keep the
chromosomes collected together, like
a tight bouquet of flowers. If the operation
is done prematurely, the chromosomes
will not be sufficiently condensed, and
too many host mitochondria will also be
flushed away. If the operation is done too
late, the chromosomes will drift apart as
the MPF activity begins to decline, prob-
ably compromising the capacity of the
sperm to trigger development. Introducing
a different set of chromosomes wrapped
inside a tiny cell membrane package is
not trivial, and delivering them intact inside
the enucleated egg is also a challenge.
Direct injection carries the risk of losing
the genetic material during their aspiration
and or ejection from the injection needle.
Fusion is the safest option but, if per-
formed with the traditional method of
using an electrical pulse, the develop-
mental potential of the egg will be compro-
mised because of premature activation.
Instead, the authors relied on one of the
oldest ‘‘tricks’’ in the book and used inac-
tivated sendai virus to fuse the two cell
membranes. While on paper this progres-
sion may seem as simple as a series of
well-orchestrated experimental steps, in
reality success depends on having top-
quality biological material and many,
many hours of training at the microscope.
If proven to translate from monkey cells
to human oocytes, the proposed use of
the technique would be for the treat-
ment—if not eradication—of human mito-
chondrial diseases in the offspring of an
affected biological mother. The scheme
necessitates that women are willing toCell Stem Celldonate their healthy eggs to those that
need them, not to mention the experi-
mental progress—and demand for human
eggs—that the translation to the clinic will
require. Thus, in addition to the technical
challenges described above, moving this
technique into a routine clinical practice
runs into an old and challenging dilemma.
Consider the recent historical example: for
almost ten years, from 1997 when the
cloned sheep Dolly was first announced
until the advent of human induced pluripo-
tent stem cells (iPSCs) in 2007 (Wilmut
et al., 1997; Takahashi et al., 2007), the
field has struggled with the ethical chal-
lenge posed by the idea of creating
patient-specific ESCs via somatic cell nu-
clear transfer (SCNT) (Cibelli et al., 2001).
Specifically, although SCNT offered hope
for those trying to help patients suffering
from devastating diseases, the technique
raised legitimate worries that the need
for human eggs could put the women
who supply them at risk, dampening the
excitement of having a new tool—albeit
a powerful one—to cure patients. Indeed,
when Takahashi et al. (2007) and Yu et al.
(2007) announced the generation of
human iPSCs, a collective sigh of relief
was almost audible, as the field embraced
an approach that promised to bypass the
need for human embryos. Nonetheless,
some scientists, and I identify myself
among them, believe that human eggs
will still be needed for some time to
come, in order to help us truly understand
their unique properties that permit dedif-
ferentiation and rejuvenation of differenti-
ated cells. Of course, such need will never
reach the proportions of what we thought
the field faced when SCNT was the only
route to generate isogenic ESCs.
Which brings us back to the implica-
tions of the new technique described by
Tachibana et al. (2009). Will the possibility5, October 2, 2009 ª2009 Elsevier Inc. 345
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PreviewsFigure 1. Timeline of Scientific Experiments Fueling the Need for Human Oocytes for
Researchof ST reignite the debate over the need for
high-quality human eggs? Considering
the devastating consequences of mito-
chondrial diseases and the possibilities
that ST can offer to parents in search of
a cure, the answer seems self evident.
How could there not be a demand to
extend their work into a human context?
Of course, given that SCNT has yet to be
conclusively translated from monkey to
human cells, future success of human
ST is far from certain. Moreover, the ques-
tion of how researchers might demon-
strate the feasibility and safety of ST
with human cells presents significant
ethical challenges in and of itself.
Nonetheless, in addition to the promise
that ST offers to those suffering from heri-
table mitochondrial disease, there is at
least one other constituency that likely
find ST technology a hopeful therapeutic
alternative. During 2006, almost 17,000
in vitro fertilization (IVF) cycles were per-
formed with donated eggs for women
whose own oocytes were, for some rea-
son, of low quality. Assuming the DNA
itself is not the reason for the failures,
human ST would likely be the first choice
for these patients, if the technology were
proven to be effective. Older women could
have children carrying their own DNA
thanks to the cytosolic contribution of a
healthy, young surrogate egg. This proce-
dure could certainly be attempted prior to
undertaking IVF with intact donor eggs,
resulting in a child related to the donor
and not the woman who carried the fetus346 Cell Stem Cell 5, October 2, 2009 ª2009to term. The long-term safety and efficacy
of the ST technique will have to be shown,
something that the Oregon team is likely
planning to undertake.
Certainly, the debate over the con-
tinuing need for donated oocytes that
we thought was put to rest in 2007 has
just been resurrected (Figure 1). And it
caught us almost as unprepared as in
1997, or worse. The legal landscape con-
cerning the compensation of egg donors
varies widely, especially across the US,
ranging from allowing for payment (New
York), to compensation for expenses
and lost wages (California), to banning it
altogether (Michigan). Perhaps it is time
to establish a comprehensive, federal
policy that would both protect women
and also sponsor the research necessary
to test whether a technique such as ST
can be used in the clinic.
The repercussions of the ST technique
go beyond its practical application in
the clinic. For years there has been a
‘‘closeted’’ debate on whether assisted
reproductive techniques such as IVF and
intracytoplasmic sperm injection (ICSI)
could have detrimental health effects on
children. The rationale for this concern is
based on evidence gathered mostly in
laboratory animals, such as the finding
that slight changes in the composition of
the medium in which mouse embryos
are cultured significantly alter its gene
expression (Rinaudo and Schultz, 2004).
Considering that the first rounds of divi-
sion in the embryo are driven by mole-Elsevier Inc.cules already present in the unfertilized
egg, its responsibility on the fate of the
offspring cannot be underestimated, and
yet has been challenging to study. ST
can help us answer some of these ques-
tions. By exploring the possibility of taking
the chromosomes from an egg—deemed
of high quality—and transferring it to the
cytosol of an egg of low quality (or
the opposite), we could not only answer
the question of how important is the
quality of the egg cytosol on the fate of
an embryo, but we could also investigate
which critical egg genes predestine the
embryo to succeed or fail; all done in
primates. But to conduct these important
basic science investigations, with the
hopes of eventually learning lessons to
benefit future reproductive technologies,
a source of human oocytes for research
will be required.
We bow to the Oregon scientists, while
we brace ourselves for the arduous
discussions to come as the field works
to implement the technique they unveiled.
Certainly, the question of what parallel
laboratory tests can be undertaken ethi-
cally with human eggs and what level of
preclinical safety assessment will be suffi-
cient to permit the translation of ST into
the clinic remain essential issues to be
addressed.
The need for human eggs for research
is back. It seems like it never left the stage
after all.
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